scispace - formally typeset
H

Hitoshi Ohmori

Researcher at Nara Medical University

Publications -  75
Citations -  2183

Hitoshi Ohmori is an academic researcher from Nara Medical University. The author has contributed to research in topics: Metastasis & Cancer. The author has an hindex of 26, co-authored 75 publications receiving 1822 citations. Previous affiliations of Hitoshi Ohmori include Fukuoka University & Okayama Gakuin University.

Papers
More filters
Journal ArticleDOI

Inhibition of heme oxygenase-1 by zinc protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL mice.

TL;DR: In contrast, CoPPIX treatment increased HO‐1 expression, enhanced tumorigenicity and MVD and reduced apoptosis, whereas cobalt PPIX (CoPPIX), an HO‐ 1 activator, increased both.
Journal ArticleDOI

Colon Cancer Cell-Derived High Mobility Group 1/Amphoterin Induces Growth Inhibition and Apoptosis in Macrophages

TL;DR: The results suggest that HMGB1/amphoterin induces growth inhibition and apoptosis in macrophages through RAGE intracellular signaling pathway.
Journal ArticleDOI

High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy.

TL;DR: It is suggested that HMGB1 released from necrotic cancer cells treated with a necrosis inducer enhances regrowth and metastasis of remnant cancer cells via RAGE activation.
Journal ArticleDOI

Cancer Usurps Skeletal Muscle as an Energy Repository

TL;DR: HMGB1 released during tumorigenesis recruits muscle to supply glutamine to cancer cells as an energy source, suggesting that cancer energy production and host muscle are linked.
Journal ArticleDOI

High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma.

TL;DR: Examination of MIA expression in 62 oral squamous cell carcinomas suggests that MIA expression is enhanced by the interaction of intracellular HMGB1 and NFkBp65 and MIA is closely involved in tumor progression and nodal metastasis by the increments of VEGF‐C and V EGF‐D in OSCC.